DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/ca50b8/uzbekistan_pharmac) has announced the addition of the "Uzbekistan Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
Uzbekistan has enormous long-term growth potential and is expected to grow by a compound annual growth rate (CAGR) of 11.15% through to 2015 in US dollar terms. However, it has serious political and economic risks due to a lack of a clear transition process for when the ageing president, Islam Karimov, leaves the scene and high levels of poverty. It is suspected that simmering social tensions are kept under control only through harsh repression. Still, for companies willing to face these major risks, the generic drugs market retains significant potential.
Headline Expenditure Projections
- Pharmaceuticals: UZS729.76bn (US$463mn) in 2010 to UZS865.43 (US$515mn) in 2011; up by 18.6% in local currency terms and 11.1% in US dollar terms. Forecast up slightly from Q311 due to macroeconomic factors and exchange rate adjustments.
- Healthcare: UZS2,680.8bn (US$1.70bn) in 2010 to UZS3,172.6bn (US$1.89bn) in 2011; up by 18.3% in local currency terms and 10.9% in US dollar terms. Forecast virtually unchanged since Q311.
- Medical devices: UZS128.9bn (US$82mn) in 2010 to UZS152.7bn (US$91mn); up by 18.5% in local currency terms and 11.0% in US dollar terms. Forecast up slightly from Q311 due to macroeconomic factors and exchange rate adjustments.
Key Trends and Developments
- The project follows Swiss-registered company Ival's plans to build an insulin factory in Uzbekistan. Previously reported to be a US$150mn project, the state-owned firm Uzpharmsanoat was quoted more recently by Russian newswires saying the project was a US$250mn investment.
Companies Mentioned:
- Jurabek Laboratories
- Uzpharmsanoat
- Asklepiy Pharmaceutical Company
For more information visit http://www.researchandmarkets.com/research/ca50b8/uzbekistan_pharmac